Previous 10 | Next 10 |
—Company also expanding its discovery platform in complement-mediated diseases, including potent, selective, oral molecules targeting C2— RESEARCH TRIANGLE PARK, N.C., Jan. 09, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced ...
Summary Baker Brothers’ 13F portfolio value decreased from $17.63B to $15.27B this quarter. Rhythm Pharma and Akero Therapeutics were increased while decreasing argenx SE and Horizon Therapeutics. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they a...
RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 41 st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 10, 2023, at 6:00 p.m. ET...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Roschetzky Photography / Shutterstock.com Tesla (NASDAQ: TSLA ) stock is in the news as price predictions continue to be a hot topic among traders after Elon Musk’s Twitter purchase. Muks original...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Getaround (NYSE: GETR ) stock is on the move Thursday despite a lack of recent news concerning the car-sharing service. Instead, investors will note that the company’s shares have been...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock BioCryst Pharmaceuticals (NASDAQ: BCRX ) stock is falling on Thursday after revealing the end of development for BCX9930 . BCX9930 was in development alongside BCX10013 as a Factor D inhibito...
RESEARCH TRIANGLE PARK, N.C., Dec. 15, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, based on new competitive data recently presented at the American Society of Hematology (ASH) annual meeting, the company no longer believes that BCX9930 wou...
RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present virtually at the JMP Securities Hematology & Oncology Summit on Wednesday, December 7, 2022, at 11:40 a.m. ET. Links to th...
RESEARCH TRIANGLE PARK, N.C., Nov. 28, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Israeli Ministry of Health has granted marketing authorization for oral, once-daily ORLADEYO ® (berotralstat) to prevent attacks of heredi...
The following slide deck was published by BioCryst Pharmaceuticals, Inc. in conjunction with this event. For further details see: BioCryst Pharmaceuticals (BCRX) Investor Presentation -Slideshow
News, Short Squeeze, Breakout and More Instantly...
BioCryst Pharmaceuticals Inc. Company Name:
BCRX Stock Symbol:
NASDAQ Market:
BioCryst Pharmaceuticals Inc. Website:
RESEARCH TRIANGLE PARK, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the General Directorate of Medicines, Supplies and Drugs (DIGEMID) in Peru has granted approval for oral, once-daily ORLADEYO ® (berotralstat) for t...
2024-06-27 04:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-07 10:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...